Market research
LX31.F Lexicon Pharmaceuticals, Inc
F EUR Not available
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 420M
- P/E ratio
- 11.62
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.46
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 420M
- P/E ratio
- 11.62
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.46
About
About Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Research context
Lexicon Pharmaceuticals, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LX31.F discussion.
5 years, 7 months ago
Lexicon Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 11.1% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.4.
Lexicon Pharmaceuticals, Inc's total revenue sank by 97.7% to $199K since the same quarter in the previous year.
Its net income has increased by 89.3% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 40.7% to $-34M since the same quarter in the previous year.
Based on the above factors, Lexicon Pharmaceuticals, Inc gets an overall score of 2/5.